Cargando…
Quality Assessment of Investigational Medicinal Products in COVID-19 Clinical Trials: One Year of Activity at the Clinical Trials Office
One year after the spread of the pandemic, we analyzed the assessment results of the quality documentation submitted to the Clinical Trials Office of the Italian Medicines Agency as part of the request for authorization of clinical trials with a COVID-19 indication. In this article, we report the cl...
Autores principales: | Dri, Diego Alejandro, Praticò, Giulia, Gaucci, Elisa, Marianecci, Carlotta, Gramaglia, Donatella |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8709226/ https://www.ncbi.nlm.nih.gov/pubmed/34959722 http://dx.doi.org/10.3390/ph14121321 |
Ejemplares similares
-
Critical Analysis and Quality Assessment of Nanomedicines and Nanocarriers in Clinical Trials: Three Years of Activity at the Clinical Trials Office
por: Dri, Diego Alejandro, et al.
Publicado: (2022) -
Surfactants, Nanomedicines and Nanocarriers: A Critical Evaluation on Clinical Trials
por: Dri, Diego Alejandro, et al.
Publicado: (2021) -
Nanomedicines and nanocarriers in clinical trials: surfing through regulatory requirements and physico-chemical critical quality attributes
por: Dri, Diego Alejandro, et al.
Publicado: (2022) -
Regulatory Considerations on the use of Machine Learning based tools in Clinical Trials
por: Massella, Maurizio, et al.
Publicado: (2022) -
Investigational Medicinal Products for the Inner Ear: Review of Clinical Trial Characteristics in ClinicalTrials.gov
por: Le Prell, Colleen G.
Publicado: (2022)